365 Desensitization¶
Chapter 365 | Part 11: Immune-Mediated, Inflammatory, and Rheumatologic Disorders
KEY CLINICAL POINTS¶
- Desensitization is a temporary immunotherapy modality used for patients with drug allergies, achieving tolerance through serial administration of escalating drug doses.
- Drug desensitization protocols vary by reaction type (Type I, II, III, IV) and include standardized multistep IV/PO/SC protocols (e.g., 3-bag 12-step, 4-bag 16-step).
- Key mechanisms include IgE-mediated mast cell inhibition, cytokine release reactions (CRRs), and T-cell-mediated delayed hypersensitivity.
- Desensitization is contraindicated in Kounis syndrome, takotsubo cardiomyopathy, and severe organ-specific toxicity; requires specialist supervision.
- Peanut oral immunotherapy (OIT) is FDA-approved for severe peanut allergy, with early introduction preventing 80% of allergies in high-risk infants.
1. DEFINITION & OVERVIEW¶
Desensitization is a temporary state of drug tolerance achieved through serial administration of escalating doses of an allergen. It is used for patients with IgE-mediated or non-IgE-mediated anaphylaxis, including drug allergies, venom allergies, and food allergies (e.g., peanut). Desensitization protocols are tailored to reaction type and patient risk factors, with the goal of safely reintroducing the drug while avoiding anaphylaxis.
Phenotype | Infusion Reaction | Type I IgE/non-IgE | Mixed | Cytokine Release | Type II | Type III | Type IV¶
| Phenotype | Infusion Reaction | Type I IgE/ non-IgE | Mixed | Cytokine Release | Type II | Type III | Type IV |
|---|---|---|---|---|---|---|---|
| Endotype | Lymphocyt e | Mast cell | Both | T cell | T cell NK cell | Antibody O psonization | Neutrophil |
| Antibody O psonization | C3a | C3a | C3a | Antigen/anti body complexes | T cell | Biomarkers | MF |
| Biomarkers | TNF-a, IL-6, IL-1b | Histamine, tryptase | Both | TNF-a, IL-6, IL-1b | IL-6, IL-1b | Specific antibody or antibody/an tibody complex deposition | IFN-g, IL-4, IL-5 |
| Phenotype | Infusion Reaction | Type I IgE/ non-IgE | Mixed | Cytokine Release | Type II | Type III | Type IV |
|---|---|---|---|---|---|---|---|
| Symptoms | Fever, Chill s/rigors, Nausea, Pain, Headache | Flushing, Pruritus, Rash, Urticaria, Throat tightness, Shortness of breath, Nausea and/or vomiting, A naphylaxis and cardiov ascular collapse | Both | Fever, Chill s/rigors, Nausea, Pain, Headache, Dyspnea, H yper/hypote nsion, Back pain | Autoimmun e, Thrombo cytopenia, Anemia, Ne utropenia | Serum sickness, Urticaria vasculitis, Arthus reaction, Nephritis, Fever | Delayed ma culopapular rash |
| Desensitiza tion | Non indicated, regular infusion | Indicated | Indicated | Indicated | Not indicated, avoid medication | Not indicated, avoid medication | Indicated |
1.1 Drug Desensitization Mechanisms¶
IgE-mediated desensitization inhibits mast cell/basophil pathways via low-dose drug antigens. Cytokine release reactions (CRRs) involve T-cell activation and interleukin (IL-6) elevation. Delayed-type IV reactions involve T-cell-mediated cytotoxicity and antigen/antibody complex deposition.
1.2 Venom Immunotherapy¶
Patients with documented Hymenoptera sting anaphylaxis should receive venom immunotherapy (VIT) with maintenance doses equivalent to 2–5 stings. Treatment duration is 3–5 years, with lifelong therapy for severe respiratory/cardiovascular anaphylaxis.
2. EPIDEMIOLOGY¶
Drug allergies are rising globally, paralleling increased medication use and new therapies. Penicillin allergy affects 10–20% of the population, with 1–2% of patients having true IgE-mediated allergies. Peanut allergy prevalence rose sharply in the 1990s–2000s, particularly in Western countries with delayed peanut introduction. Early peanut introduction (before 1 year) reduces allergy risk by 80%.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Drug allergies involve IgE-mediated mast cell activation, cytokine release reactions (CRRs), or T-cell-mediated delayed hypersensitivity. IgE sensitization requires repeated exposure, while non-IgE reactions occur at first exposure via complement activation, COX-1 inhibition, or MRGPRX2 receptor activation. CRRs are associated with IL-6 elevation and T-cell activation, while delayed reactions involve antigen/antibody complex deposition and neutrophil infiltration.
4. CLINICAL FEATURES¶
Acute reactions include flushing, urticaria, angioedema, dyspnea, hypotension, and elevated tryptase. Delayed reactions present with maculopapular rashes, serum sickness, or severe cutaneous adverse reactions (SCARS) like Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Mixed reactions combine features of Type I and CRRs.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include non-allergic drug reactions (e.g., pseudoallergies), infections, and other systemic conditions. Mixed reactions (Type I + CRR) must be distinguished from pure Type I or Type IV reactions based on biomarkers (tryptase, IL-6) and temporal patterns.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis involves skin testing (ST) for IgE-mediated reactions, basophil activation tests (BAT) for IgE sensitization, and lymphocyte transformation tests (LTT) for delayed reactions. Serum-specific IgE and tryptase levels are critical for anaphylaxis confirmation. Positive ST or BAT results confirm IgE-mediated allergy, while delayed reactions require patch testing or cytokine profiling.
7. MANAGEMENT & TREATMENT¶
Desensitization protocols include multistep IV/PO/SC regimens (e.g., 3-bag 12-step, 4-bag 16-step). Premedication with antihistamines, corticosteroids, and epinephrine is standard. For peanut allergy, oral immunotherapy (OIT) is FDA-approved. Venom immunotherapy (VIT) uses serial subcutaneous allergen doses. Breakthrough reactions (BTRs) require symptom-specific management and may necessitate protocol modification.
Desensitization Protocols¶
| Protocol | Dose Bags | Steps | Duration | Rate (mL/h) |
|---|---|---|---|---|
| 4-bag 16-step | 1/1000, 1/100, 1/10, Full dose | 16 | 6.7h | 2.5 X 15min, 5 X 15min, 10 X 13min, 20 X 15min, ... |
| 3-bag 12-step | 1/100, 1/10, Full dose | 12 | 5.7h | 2.5 X 15min, 5 X 15min, 10 X 15min, 20 X 15min, ... |
| 2-bag 8-step | 1/10, Full dose | 8 | 4.3h | 5 X 15min, 10 X 15min, 20 X 15min, ... |
| 1-bag 4-step | Full dose | 4 | 2.9h | 10 X 15min, 20 X 15min, 40 X 15min, 80 X 15min |
7.1 Desensitization Protocols¶
Standardized protocols include: 3-bag 12-step (5.7h), 4-bag 16-step (6.7h), and one-bag 4-step for mild reactions. Rates: 2.5–80 mL/h with 15-min intervals. For delayed reactions, multi-day incremental dosing is used.
7.2 Drug-Specific Protocols¶
Taxanes (paclitaxel/docetaxel): 3-bag 12-step with premedication. Platinums (carboplatin): 3-bag 12-step with epinephrine. Monoclonals (rituximab/cetuximab): 3-bag 12-step with corticosteroids.
8. PROGNOSIS & COMPLICATIONS¶
Desensitization is temporary and requires repeated administration. Complications include breakthrough reactions (BTRs), anaphylaxis, and Kounis syndrome. Long-term tolerance is rare; patients may return to regular infusions after successful desensitization. Mortality is rare (<1% in studies).
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Safe for desensitization with appropriate monitoring. Pediatrics: Early peanut introduction reduces allergy risk. Elderly: Higher risk of BTRs due to comorbidities. Patients with mastocytosis or HLA-associated SCARS require lifelong therapy.
10. KEY POINTS & CLINICAL PEARLS¶
- Desensitization is indicated for IgE-mediated and non-IgE drug allergies, with protocols tailored to reaction type. 2. Use standardized multistep IV/PO/SC protocols (e.g., 3-bag 12-step) for most reactions. 3. Premedication with antihistamines, corticosteroids, and epinephrine is critical. 4. Peanut OIT is FDA-approved for severe allergy. 5. Avoid desensitization in Kounis syndrome or severe organ toxicity. 6. Early peanut introduction reduces allergy risk by 80% in high-risk infants.